Search Results 991-1000 of 17741 for corticosteroid

1. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Treatment with corticosteroids within 2 weeks of the first dose of study drug, except for the equivalent of ≤ 10 mg prednisone per day or corticosteroids ...

2. Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) - Mayo Clinic

   Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot ...

3. CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies - Mayo Clinic

   * Current need of systemic corticosteroid therapy, in doses over 20 mg /day of prednisone or equivalent forms of steroids * History of severe immediate ...

4. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab - Mayo Clinic

   physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy - Patients who are ...

5. Folliculitis - Symptoms & causes - Mayo Clinic

   Using some medications, such as corticosteroid creams, prednisone, long-term antibiotic therapy for acne and certain chemotherapy drugs; Having dermatitis or ...

6. A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV) - Mayo Clinic

   Corticosteroid treatment (e.g., prednisone, solumedrol) within 30 days of Baseline 13. Treatment with any of the following classes of nonsteroidal anti ...

7. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   ... corticosteroids within the previous 12 months. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced ...

8. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer - Mayo Clinic

   Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone (or equivalent) once daily. Active or symptomatic viral ...

9. Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma - Mayo Clinic

   Systemic corticosteroids within 24 hours prior to study drug administration. Symptoms of cardiac failure with New York Heart Association classification of ...

10. Long-term Safety and Effectiveness Study for Participants with Advanced Tumors who are Currently on Treatment or in Follow-up in a Pembrolizumab Trial - Mayo Clinic

    years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive ... Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid